Bionomics announced on 23 May 2018 it has initiated a Phase IIa study of its α7 nicotinic receptor inhibitor for the treatment of agitation in the elderly in a hospital setting. Agitation is a common problem (13-24%) in patients with dementia, and we expect the trial to focus primarily on this population. It will enrol a target of 40 patients across Australia and is expected to provide top-line data in calendar Q119.
29 May 2018
Bionomics - Phase IIa in agitation of the elderly initiated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bionomics - Phase IIa in agitation of the elderly initiated
- Published:
29 May 2018 -
Author:
Dr Nathaniel Calloway -
Pages:
6
Bionomics announced on 23 May 2018 it has initiated a Phase IIa study of its α7 nicotinic receptor inhibitor for the treatment of agitation in the elderly in a hospital setting. Agitation is a common problem (13-24%) in patients with dementia, and we expect the trial to focus primarily on this population. It will enrol a target of 40 patients across Australia and is expected to provide top-line data in calendar Q119.